SBWire

Despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy according to a recent paper in Current Opinion in Oncology.

Global Markets Direct's, 'Japanese Encephalitis - Pipeline Review, H2 2014', provides an overview of the Japanese Encephalitis's therapeutic pipeline.

OTC Medications in Sweden by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Sweden is given in SEK with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Sweden. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it acquired the worldwide rights to the Fluticare(TM) brand (Fluticasone propionate nasal spray) from Novalere FP., Inc. ("Novalere") through a merger.

Actinium Pharmaceuticals, Inc.("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors. Prior to founding TurckBio, Dr. Turck led Bayer Healthcare's Global Specialty Medicine unit, where most relevant to Actinium, he played a leadership role in the commercialization of the alpha-radiopharmaceutical Xofigo® whose successful launch he prepared in close collaboration with Algeta ASA.

OTC Medications in Italy by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Italy is given in EUR with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Italy. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Global Markets Direct's, 'Nuevolution A/S - Product Pipeline Review - 2014', provides an overview of the Nuevolution A/S's pharmaceutical research and development focus.

Global Markets Direct's, 'HAL Allergy BV - Product Pipeline Review - 2014', provides an overview of the HAL Allergy BV's pharmaceutical research and development focus.

Global Markets Direct's, 'Panmira Pharmaceuticals, LLC. - Product Pipeline Review - 2014', provides an overview of the Panmira Pharmaceuticals, LLC.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Peripheral Neuropathic Pain's therapeutic pipeline.

GlobalData's clinical trial report, "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014" provides data on the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Clostridium Difficile Infections (Clostridium Difficile Associated Disease). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Clostridium Difficile Infections (Clostridium Difficile Associated Disease). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NovaDigm Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Cleveland BioLabs, Inc. - Product Pipeline Review - 2014', provides an overview of the Cleveland BioLabs, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Parion Sciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Parion Sciences, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'NeoStem, Inc. - Product Pipeline Review - 2014', provides an overview of the NeoStem, Inc.'s pharmaceutical research and development focus.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and vitality, announced today that it entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Androferti®, a patented and clinically proven product to support male reproductive health and sperm quality, in the U.S. and Canada.

Global Markets Direct's, 'Syntiron LLC - Product Pipeline Review - 2014', provides an overview of the Syntiron LLC's pharmaceutical research and development focus.

Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H2 2014', provides an overview of the Raynauds Disease's therapeutic pipeline.

GlobalData has released its new PharmaPoint Drug Evaluation report, "Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Global Markets Direct's, 'X-BODY BioSciences, Inc. - Product Pipeline Review - 2014', provides an overview of the X-BODY BioSciences, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Virometix AG - Product Pipeline Review - 2014', provides an overview of the Virometix AG's pharmaceutical research and development focus.

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

Global Markets Direct's, 'Sensorion S.A.S. - Product Pipeline Review - 2014', provides an overview of the Sensorion S.A.S.'s pharmaceutical research and development focus.

Global Markets Direct's, 'AtheroNova Inc. - Product Pipeline Review - 2014', provides an overview of the AtheroNova Inc.'s pharmaceutical research and development focus.